Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

15.73
+0.29001.88%
Post-market: 15.730.00000.00%19:35 EDT
Volume:3.99M
Turnover:63.05M
Market Cap:4.06B
PE:4.72
High:16.08
Open:15.36
Low:15.33
Close:15.44
Loading ...

Organon & Co -on Sept 17, Co & Unit Entered Into Agreement and Plan of Merger by Dermavant Sciences & Roivant Sciences

THOMSON REUTERS
·
24 Sep 2024

Court revives more than 500 lawsuits over Fosamax femur fracture risk

Reuters
·
21 Sep 2024

Barclays Keeps Their Buy Rating on Organon (OGN)

TIPRANKS
·
19 Sep 2024

Evercore ISI Sticks to Their Buy Rating for Organon (OGN)

TIPRANKS
·
18 Sep 2024

Organon Shares Down 1.3%

THOMSON REUTERS
·
18 Sep 2024

Roivant Sciences Shares up 2% After Organon Agrees to Buy Co's Unit for up to $1.2 Billion

THOMSON REUTERS
·
18 Sep 2024

BRIEF-Organon To Acquire Dermavant Including Its Innovative Dermatologic Therapy, Vtama® (Tapinarof) Cream, 1%

Reuters
·
18 Sep 2024

Roivant Sciences Shares up 3.3% Premarket After Organon Agrees to Buy Co's Unit for up to $1.2 Billion

THOMSON REUTERS
·
18 Sep 2024

BUZZ-Roivant rises as Organon agrees to buy its unit for up to $1.2 billion

Reuters
·
18 Sep 2024

Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion

Dow Jones
·
18 Sep 2024

Organon to Acquire Dermavant for $1.2 Billion

MT Newswires Live
·
18 Sep 2024

UPDATE 1-Organon to buy skin therapy developer Dermavant for up to $1.2 billion

Reuters
·
18 Sep 2024

Organon to buy therapy developer Dermavant for up to $1.2 billion

Reuters
·
18 Sep 2024

Organon to Acquire Dermavant Including Its Innovative Dermatologic Therapy, Vtama® (Tapinarof) Cream, 1%

THOMSON REUTERS
·
18 Sep 2024

Organon & Co-FDA Reviewing Snda for Vtama Cream as Potential Treatment for Ad in Adults & Children 2 Yrs of Age &Older,With Pdufa Action Sees in Q4

THOMSON REUTERS
·
18 Sep 2024

Organon & Co: Deal to Be Modestly Dilutive to Adj Ebitda in 2025, Turning Accretive in 2026

THOMSON REUTERS
·
18 Sep 2024